Status:
WITHDRAWN
Roflumilast TMS-EEG Plasticity
Lead Sponsor:
University of Calgary
Conditions:
Synaptic Plasticity
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
Repetitive transcranial magnetic stimulation (rTMS) uses a magnetic field to non-invasively induce electrical function within the brain. Stimulation allows brain cells to change the way that they adap...
Detailed Description
This randomized, placebo-controlled, crossover trial will enroll 20 healthy participants. In one arm of the study, participants will randomly receive either 250mcg of roflumilast (a phosphodiesterase-...
Eligibility Criteria
Inclusion
- Healthy individuals (no chronic medical conditions).
- Aged 18-60 years.
Exclusion
- Pregnancy
- Lactation
- Epilepsy
- Previous stroke
- Current Renal Disease
- Current Liver Disease
- Allergy to roflumilast or any of its non-medicinal ingredients
- Current psychiatric concerns
- Currently taking any medications that interact with roflumilast
- Intracranial metallic objects (dental hardware is not an exclusionary criterion)
- Substance use disorder
- The inability to refrain from alcohol use for 24 hours prior to stimulation
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04369547
Start Date
January 1 2022
End Date
September 1 2023
Last Update
December 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary
Calgary, Alberta, Canada, T2N1N4